Ipsen has agreed to acquire Swiss biotech Memo Therapeutics in a deal valued at up to $800 million. The acquisition centers on an experimental medicine currently in late-stage testing for a virus that frequently strikes kidney transplant recipients.
The therapy targets a specific virus that poses significant risk to immunocompromised patients, particularly those who have undergone kidney transplantation. The deal includes an upfront payment plus milestone-based contingent payments that could reach the full $800 million figure.
The experimental medicine is in late-stage clinical testing, positioning Ipsen to potentially bring a new treatment option to a vulnerable patient population. No specific efficacy or safety data from the trials has been disclosed in the acquisition announcement.
For Ipsen, the deal expands its rare disease pipeline and adds a late-stage asset with potential regulatory filings on the horizon. The acquisition underscores the company's strategy to bolster its portfolio through targeted bolt-on purchases rather than large-scale mergers.
The transaction is expected to close in the coming months, subject to regulatory approvals and customary closing conditions. Memo Therapeutics shareholders are set to receive consideration through the deal structure.